<DOC>
	<DOCNO>NCT00085501</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining one chemotherapy drug monoclonal antibody may kill tumor cell . It yet know whether cetuximab effective give time chemotherapy follow chemotherapy . PURPOSE : This randomized phase II trial study well give cetuximab time combination chemotherapy work compare give cetuximab combination chemotherapy treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>S0342 : Paclitaxel , Carboplatin , Cetuximab Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient select stage IIIB stage IV non-small cell lung cancer treat concurrent v sequential paclitaxel , carboplatin , cetuximab . Secondary - Compare response rate ( confirm unconfirmed , complete partial ) patient treat regimen . - Compare toxic effect regimens patient . - Correlate epidermal growth factor receptor polymorphisms downstream biomarkers response cetuximab patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( concurrent cetuximab ) : Patients receive cetuximab IV 1 hour ( 2 hour day 1 course 1 ) day 1 , 8 , 15 paclitaxel IV 3 hour carboplatin IV 30 minute day 8 . Treatment repeat every 21 day total 4 course ( 12 week ) absence disease progression unacceptable toxicity . Beginning week 13 , patient receive single-agent cetuximab IV 1 hour weekly absence disease progression unacceptable toxicity . - Arm II ( sequential cetuximab ) : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 21 day total 4 course ( 12 week ) absence disease progression unacceptable toxicity . Beginning week 13 , patient receive single-agent cetuximab IV 1 hour ( 2 hour week 13 ) weekly absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 180 patient ( 90 per treatment arm ) accrue study within 9 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) one follow stage : Newly diagnose select stage IIIB disease ( T4 lesion due malignant pleural effusion , N , M0 ) Newly diagnose stage IV disease ( T , N , M1 ) Recurrent stage IV disease prior surgery radiotherapy The following subtypes eligible : Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Unspecified Measurable disease CT scan , MRI , xray , physical exam Pleural effusion , ascites , laboratory parameter acceptable evidence disease Not within prior radiotherapy field unless new lesion present Not within area prior surgical resection No known brain metastasis CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 mg/dL Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT SGPT ≤ 2 time ULN Alkaline phosphatase ≤ 2 time ULN No known acute hepatitis Renal Creatinine ≤ ULN Creatinine clearance ≥ 50 mL/min Cardiovascular No significant cardiac disease No uncontrolled hypertension No unstable angina No congestive heart failure Other No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission No active uncontrolled infection No sensory neuropathy ≥ grade 2 No know human antimouse antibody Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy NSCLC No prior chimeric murine monoclonal antibody therapy No prior cetuximab Chemotherapy No prior systemic chemotherapy NSCLC Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery See Disease Characteristics At least 2 week since prior thoracic major surgery recover Other No prior gefitinib investigational agent target epidermal growth factor receptor pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
</DOC>